Assessing the safety of SARS-CoV-2 mRNA vaccines and the effect of immunotherapies on the seroconversion rate in patients with autoimmune neurological conditions (ANC) is relevant to clinical practice. Our aim was to assess the antibody response to and safety of SARS-CoV-2 mRNA vaccines in ANC.
Giannoccaro, M.P., Vacchiano, V., Leone, M., Camilli, F., Zenesini, C., Panzera, I., et al. (2022). Difference in safety and humoral response to mRNA SARS-CoV-2 vaccines in patients with autoimmune neurological disorders: the ANCOVAX study. JOURNAL OF NEUROLOGY, 269(8), 4000-4012 [10.1007/s00415-022-11142-7].
Difference in safety and humoral response to mRNA SARS-CoV-2 vaccines in patients with autoimmune neurological disorders: the ANCOVAX study
Giannoccaro, Maria Pia
;Vacchiano, Veria;Leone, Marta;Camilli, Federico;Zenesini, Corrado;Balboni, Alice;Salvi, Fabrizio;Lugaresi, AlessandraWriting – Review & Editing
;Di Felice, Giulia;Lazzarotto, Tiziana;Liguori, Rocco
2022
Abstract
Assessing the safety of SARS-CoV-2 mRNA vaccines and the effect of immunotherapies on the seroconversion rate in patients with autoimmune neurological conditions (ANC) is relevant to clinical practice. Our aim was to assess the antibody response to and safety of SARS-CoV-2 mRNA vaccines in ANC.File in questo prodotto:
Eventuali allegati, non sono esposti
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
